Trending...
- DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
- GMO Miner: Creating a simple, efficient and reliable new cloud mining experience
- purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
FAYETTEVILLE, Ark. - PrAtlas -- Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China. These patents strengthen Lineus Medical's intellectual property portfolio as the company continues expanding into major healthcare markets worldwide. They also mark a key milestone toward obtaining regulatory clearances and establishing distribution partnerships in these regions.
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on PrAtlas
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on PrAtlas
- Mortgage Rates And Demand Are Stuck In A Holding Pattern
- Coker Completes Acquisition of Healthcare Cost Solutions, a Leading Expert in Technology-Enabled Compliance Services
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- K2 Integrity's U.S. and EMEA Teams Recognized in Chambers and Partners 2025 Guides
- A rare chance to own a multi-family property in the heart of Bay Ridge
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
Source: Lineus Medical
0 Comments
Latest on PrAtlas
- Lottery.com Inc. Secures $300 Million in Growth Capital, Confirms Nasdaq Compliance & Acquires UAE Sports Incubator Amid High-Profile Brand Exposure
- $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
- NUFABRX awarded Therapeutic Compression agreement with Premier, Inc
- Luxurious Estate in Keenes Pointe Hits the Market at $2.9 Million
- CredHub and ManageAmerica Partner to Empower Residents Through Seamless Rent Reporting Integration
- TKSoftware Inc. Unveils ICONIC Pro: The All‑In‑One Medical Billing & Clearinghouse Solution
- Baker Rights and Coercive Psychiatry: The Citizens Commission on Human Rights of Florida Hosts Monthly Mental Health Law and Human Rights Seminars
- Venardi Zurada LLP Offers Legal Support to Families After Deadly Lake Tahoe Boat Capsizing
- Elevated Healing Treatment Centers: Redefining Mental Health Care with Compassionate, Evidence-Based, and Accessible Services
- Carlonoscopen Launches Base-Zero Number System — A New Mathematical Language for Tomorrow's Tech
- New Study Reveals Nearly Half Of TikTok Shop Stores Generate Zero Sales Despite Platform's $100 Million Black Friday Success
- Speranza Dental Implant Centers Opens Their First Location
- WWSG Announces Exclusive Speaking Partnership with Former Australian Prime Minister Tony Abbott
- Aidaptive and BizCor Expand Inhabit Partnership with Native Enterprise-Grade Search for Streamline Customers
- Pikmykid Partners with Vivi to Enhance School Emergency Communication and Safety
- AI Meets Cybersecurity: IQSTEL and Cycurion Take Aim at $500 Billion Market Opportunity
- N A S D A Q Compliance Achieved Following Active Trading and Financing, UAE Acquisition & Major Brand Events: Lottery.com Inc., (N A S D A Q: LTRY)
- New Frontier Aerospace Successfully Tests Its Revolutionary Mjölnir Rocket Engine
- Profiting from Elder Harm: The Push to End Psychiatric Drugging in Nursing Homes
- LET Mining launches zero-cost cloud mining, daily rewards + referral double benefits